Omega 3: Where Do We Stand?

Author： Versari Daniele Daghini Elena Salvetti Guido Salvetti Antonio

ISSN： 1120-9879

Source： High Blood Pressure & Cardiovascular Prevention, Vol.15, Iss.4, 2008-01, pp. : 225-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Challenges of RSV Vaccines. Where do we Stand?

Recent Patents on Anti-Infective Drug Discovery, Vol. 5, Iss. 2, 2010-06 ,pp. : 99-108

Bentham Science Publishers

Access to resources Recommend Favorite

Imaging Subclinical Atherosclerosis: Where Do We Stand?

Current Cardiology Reviews, Vol. 13, Iss. 1, 2016-11 ,pp. : 47-55

Bentham Science Publishers

Access to resources Recommend Favorite

Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?

By Chapman Kenneth R.

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 10, Iss. 2, 2013-03 ,pp. : 243-249

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin Receptor Blockers: When Do We Prescribe Them in Patients with Diabetes Mellitus?

By Ruilope M.

High Blood Pressure & Cardiovascular Prevention, Vol. 10, Iss. 1, 2003-01 ,pp. : 47-49

Adis International

Access to resources Recommend Favorite

Do we need assessment of nonpulmonary vein triggers for successful ablation of atrial fibrillation?

By Wichterle Dan

Future Cardiology, Vol. 9, Iss. 4, 2013-07 ,pp. : 471-474

Future Medicine

Access to resources Recommend Favorite